Recruiting PHASE4 INTERVENTIONAL 1-arm NCT06357598

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer (PILOT)

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Newly Diagnosed Stage Ⅲ Unresectable Non-small Cell Lung Cancer: a Open-label, Single-arm Prospective Clinical Trial

Sponsor: The Affiliated Hospital of Qingdao University

Conditions Non-small-cell Lung Cancer (NSCLC)

Interventions Carboplatin or Cisplatin Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC) Surgery Tislelizumab

Updated 3 times since 2024 Last updated: Apr 7, 2024 Started: Jan 18, 2024 Primary completion: Dec 31, 2024 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Non-small-cell Lung Cancer (NSCLC), this trial is actively recruiting participants. The trial is conducted by The Affiliated Hospital of Qingdao University and has accumulated 3 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
May 2024 — Jul 2024 [monthly]

Recruiting PHASE4

First recorded

Jan 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Affiliated Hospital of Qingdao University

Data source: The Affiliated Hospital of Qingdao University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Qingdao, China